Hansoh Pharmaceutical Group (SHSC:3692) - Aktienkurs, Nachrichten und Analyse

3692 Aktienübersicht

Hansoh Pharmaceutical Group Company Limited, eine Investment-Holdinggesellschaft, ist in der Forschung, Entwicklung, Herstellung und dem Verkauf von pharmazeutischen Produkten in der Volksrepublik China tätig. Mehr Details

3692 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	1/6
Vergangene Leistung	5/6
Finanzielle Gesundheit	5/6
Dividenden	2/6

Belohnungen

36.5% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 2.66% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 83.1%

Analysten sind sich einig, dass der Aktienkurs um 35%

Risikoanalyse

Signifikante Insiderverkäufe in den letzten 3 Monaten

Hansoh Pharmaceutical Group Company Limited Wettbewerber

CSPC Pharmaceutical Group

SEHK:1093

HK$60.3b

Sino Biopharmaceutical

SEHK:1177

HK$59.5b

China Resources Pharmaceutical Group

SEHK:3320

HK$34.1b

China Medical System Holdings

SEHK:867

HK$18.6b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Hansoh Pharmaceutical Group
Historische Aktienkurse
Aktueller Aktienkurs	HK$17.16
52-Wochen-Hoch	HK$22.80
52-Wochen-Tief	HK$11.18
Beta	0.65
11 Monat Veränderung	-22.18%
3 Monate Veränderung	-6.54%
1 Jahr Veränderung	17.37%
33 Jahre Veränderung	-1.94%
5 Jahre Veränderung	-32.57%
Veränderung seit IPO	-31.08%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	3692	HK Pharmaceuticals	HK Markt
7D	-1.3%	-2.1%	0.05%
1Y	17.4%	-9.4%	11.5%

Rendite im Vergleich zur Industrie: 3692 übertraf die Branche Hong Kong Pharmaceuticals , die im vergangenen Jahr eine Rendite von -9.4 erzielte.

Rendite vs. Markt: 3692 übertraf den Markt Hong Kong, der im vergangenen Jahr eine Rendite von 11.5 erzielte.

Preisvolatilität

Is 3692's price volatile compared to industry and market?
3692 volatility
3692 Average Weekly Movement	7.6%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.2%

Stabiler Aktienkurs: 3692 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: 3692Die wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1995	9,099	Huijuan Zhong	www.hspharm.com

Hansoh Pharmaceutical Group Company Limited, eine Investment-Holdinggesellschaft, ist in der Volksrepublik China in der Forschung, Entwicklung, Herstellung und dem Verkauf von pharmazeutischen Produkten tätig. Das Unternehmen bietet Produkte für verschiedene therapeutische Bereiche an, darunter Tumorbekämpfung, Infektionsbekämpfung, Erkrankungen des zentralen Nervensystems, Onkologie, Stoffwechsel- und Autoimmunkrankheiten usw. Zu seinen wichtigsten Produkten gehören Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui und Puruian Tabletten.

Hansoh Pharmaceutical Group Company Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Hansoh Pharmaceutical Group im Vergleich zum Marktanteil des Unternehmens?
3692 grundlegende Statistiken
Marktanteil	HK$101.83b
Gewinn(TTM)	HK$5.07b
Umsatz(TTM)	HK$13.01b

20.1x

Kurs-Gewinn-Verhältnis

7.8x

Kurs-Umsatz-Verhältnis

Ist 3692 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
3692 Gewinn- und Verlustrechnung (TTM)
Einnahmen	CN¥12.10b
Kosten der Einnahmen	CN¥1.09b
Bruttogewinn	CN¥11.01b
Sonstige Ausgaben	CN¥6.30b
Umsatz	CN¥4.71b

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.79
Bruttomarge	91.01%
Nettogewinnspanne	38.97%
Schulden/Eigenkapital-Verhältnis	0.1%

Wie hat sich 3692 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

2.3%

Aktuelle Dividendenrendite

40%

Ausschüttungsquote

3692 Aktienübersicht

Belohnungen

Risikoanalyse

Hansoh Pharmaceutical Group Company Limited Wettbewerber

SEHK:1093

HK$60.3b

SEHK:1177

HK$59.5b

SEHK:3320

HK$34.1b

SEHK:867

HK$18.6b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093

Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

Recent updates

Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093

Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024

Now 22% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China

Now 22% undervalued

Upcoming dividend of HK$0.14 per share

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 24% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets

Now 20% undervalued

Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice

Investor sentiment improves as stock rises 24%

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"

Upcoming dividend of HK$0.071 per share at 1.4% yield

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)

Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023

Investor sentiment deteriorates as stock falls 19%

Now 25% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration

Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice

Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules

Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc

Upcoming dividend of HK$0.05 per share at 0.7% yield

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021)

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor

Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"

Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.05 per share

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022

First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021)

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.09 per share

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Financial Year End December 31, 2021, Payable on July 15, 2022

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application for the New Indication of Pegmolesatide Injections

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Hansoh Pharmaceutical Group Company Limited Announces Final Dividend for the Year Ended December 31, 2021, payable on July 5, 2022

Erträge & Einnahmen